Increased CDK5 expression in HIV encephalitis contributes to neurodegeneration via tau phosphorylation and is reversed with roscovitine

American Journal of Pathology

Volumn 178, Issue 4, 2011, Pages 1646-1661

  Patrick, Christina ^a   Crews, Leslie ^a   Desplats, Paula ^a   Dumaop, Wilmar ^b   Rockenstein, Edward ^a   Achim, Cristian L ^c   Everall, Ian P ^c,d   Masliah, Eliezer ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 5; PROTEIN P35; ROSCOVITINE; TAU PROTEIN;

ADULT; ARTICLE; ASTROCYTOSIS; CLINICAL ARTICLE; DENDRITE; DISEASE ASSOCIATION; ENZYME ACTIVATION; FEMALE; FRONTAL CORTEX; GENE SILENCING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS ENCEPHALITIS; MALE; MAZE TEST; NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; VIRUS ENCEPHALITIS;

EID: 79953666757     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2010.12.033     Document Type: Article

References (97)

1. Gendelman HE, Persidsky Y, Ghorpade A, Limoges J, Stins M, Fiala M, Morrisett R: The neuropathogenesis of the AIDS dementia complex. AIDS 1997, 11 Suppl A:S35-S45
2. McArthur J: Neurological manifestations of AIDS. Medicine 1987, 66:407-437
3. McArthur JC, Haughey N, Gartner S, Conant K, Pardo C, Nath A, Sacktor N: Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol 2003, 9:205-221 (Pubitemid 36656454)
4. González-Scarano F, Martín-García J: The neuropathogenesis of AIDS. Nat Rev Immunol 2005, 5:69-81
5. Bell JE: An update on the neuropathology of HIV in the HAART era. Histopathology 2004, 45:549-559
6. Gray F, Chrétien F, Vallat-Decouvelaere AV, Scaravilli F: The changing pattern of HIV neuropathology in the HAART era. J Neuropathol Exp Neurol 2003, 62:429-440 (Pubitemid 36560185)
7. Crews L, Patrick C, Achim CL, Everall IP, Masliah E: Molecular pathology of neuro-AIDS (CNS-HIV). Int J Mol Sci 2009, 10:1045-1063
8. Everall IP, Hansen LA, Masliah E: The shifting patterns of HIV encephalitis neuropathology. Neurotox Res 2005, 8:51-61
9. Lawrence DM, Major EO: HIV-1 and the brain: connections between HIV-1-associated dementia, neuropathology and neuroimmunology. Microbes Infect 2002, 4:301-308 (Pubitemid 34293635)
10. Diesing TS, Swindells S, Gelbard H, Gendelman HE: HIV-1-associated dementia: a basic science and clinical perspective. AIDS Read 2002, 12:358-368 (Pubitemid 34920379)
11. Masliah E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, Mallory M, Achim CL, McCutchan JA, Nelson JA, Atkinson JH, Grant I: Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group The HIV Neurobehavioral Research Center. Ann Neurol 1997, 42:963-972 (Pubitemid 28008427)
12. Masliah E, Ge N, Achim CL, DeTeresa R, Wiley CA: Patterns of neurodegeneration in HIV encephalitis. J NeuroAIDS 1996, 1:161-173
13. Masliah E, Ge N, Mucke L: Pathogenesis of HIV-1 associated neurodegeneration. Crit Rev Neurobiol 1996, 10:57-67 (Pubitemid 26283955)
14. Wiley CA, Achim CL: Human immunodeficiency virus encephalitis and dementia. Ann Neurol 1995, 38:559-560
15. Wendel KA, McArthur JC: Acute meningoencephalitis in chronic human immunodeficiency virus (HIV) infection: putative central nervous system escape of HIV replication. Clin Infect Dis 2003, 37:1107-1111 (Pubitemid 37323667)
16. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L: HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002, 8:136-142 (Pubitemid 34520894)
17. Maschke M, Kastrup O, Esser S, Ross B, Hengge U, Hufnagel A: Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). J Neurol Neurosurg Psychiatry 2000, 69:376-380 (Pubitemid 30636242)
18. Grant I, Heaton R, Atkinson J, Group H: Neurocognitive disorder in HIV-1 infection. HIV and dementia: proceedings of the NIMH-sponsored conference "Pathogenesis of HIV infection of the brain: impact on function and behavior." Edited by MBA Oldstone, L Vitkovic. Heidelberg, Springer-Verlag, 1995, pp. 9-30
19. Nath A: Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis 2002, 186 Suppl 2:S193-S198
20. Kaul M, Lipton SA: Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci USA 1999, 96:8212-8216 (Pubitemid 29328434)
21. Meucci O, Fatatis A, Simen AA, Bushell TJ, Gray PW, Miller RJ: Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc Natl Acad Sci USA 1998, 95:14500-14505 (Pubitemid 28549396)
22. Sanders VJ, Pittman CA, White MG, Wang G, Wiley CA, Achim CL: Chemokines and receptors in HIV encephalitis. AIDS 1998, 12:1021-1026
23. Giulian D, Vaca K, Noonan C: Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. Science 1990, 250:1593-1596 (Pubitemid 120034376)
24. Pulliam L, Zhou M, Stubblebine M, Bitler CM: Differential modulation of cell death proteins in human brain cells by tumor necrosis factor alpha and platelet activating factor. J Neurosci Res 1998, 54:530-538 (Pubitemid 28507031)
25. Pulliam L, Clarke JA, McGuire D, McGrath MS: Investigation of HIV-infected macrophage neurotoxin production from patients with AIDS dementia. Adv Neuroimmunol 1994, 4:195-198 (Pubitemid 24325864)
26. Wang Z, Trillo-Pazos G, Kim SY, Canki M, Morgello S, Sharer LR, Gelbard HA, Su ZZ, Kang DC, Brooks AI, Fisher PB, Volsky DJ: Effects of human immunodeficiency virus type 1 on astrocyte gene expression and function: potential role in neuropathogenesis. J Neurovirol 2004, 10 Suppl 1:25-32 (Pubitemid 38325090)
27. Brandimarti R, Khan MZ, Fatatis A, Meucci O: Regulation of cell cycle proteins by chemokine receptors: a novel pathway in human immunodeficiency virus neuropathogenesis? J Neurovirol 2004, 10 Suppl 1:108-112
28. Martín-García J, Kolson DL, González-Scarano F: Chemokine receptors in the brain: their role in HIV infection and pathogenesis. AIDS 2002, 16:1709-1730
29. Ozdener H: Molecular mechanisms of HIV-1 associated neurodegeneration. J Biosci 2005, 30:391-405
30. Lipton S: HIV-related neuronal injury. Potential therapeutic intervention with calcium channel antagonists and NMDA antagonists. Mol Neurobiol 1994, 8:181-196
31. Garden GA, Budd SL, Tsai E, Hanson L, Kaul M, D'Emilia DM, Friedlander RM, Yuan J, Masliah E, Lipton SA: Caspase cascades in human immunodeficiency virus-associated neurodegeneration. J Neurosci 2002, 22:4015-4024 (Pubitemid 37465710)
32. Alirezaei M, Watry DD, Flynn CF, Kiosses WB, Masliah E, Williams BR, Kaul M, Lipton SA, Fox HS: Human immunodeficiency virus-1/surface glycoprotein 120 induces apoptosis through RNA-activated protein kinase signaling in neurons. J Neurosci 2007, 27:11047-11055 (Pubitemid 47574170)
33. Hashimoto M, Sagara Y, Everall IP, Mallory M, Everson A, Langford D, Masliah E: Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3beta pathway. Implications for neuroprotection. J Biol Chem 2002, 277:32985-32991 (Pubitemid 34984813)
34. Maggirwar SB, Tong N, Ramirez S, Gelbard HA, Dewhurst S: HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity. J Neurochem 1999, 73:578-586 (Pubitemid 29339830)
35. Dewhurst S, Maggirwar SB, Schifitto G, Gendelman HE, Gelbard HA: Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS. J Neuroimmune Pharmacol 2007, 2:93-96
36. Wang Y, White MG, Akay C, Chodroff RA, Robinson J, Lindl KA, Dichter MA, Qian Y, Mao Z, Kolson DL, Jordan-Sciutto KL: Activation of cyclin-dependent kinase 5 by calpains contributes to human immunodeficiency virus-induced neurotoxicity. J Neurochem 2007, 103:439-455 (Pubitemid 47498010)
37. Baumann K, Mandelkow EM, Biernat J, Piwnica-Worms H, Mandelkow E: Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett 1993, 336:417-424 (Pubitemid 24036992)
38. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH: Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000, 405:360-364 (Pubitemid 30337070)
39. Qu D, Rashidian J, Mount MP, Aleyasin H, Parsanejad M, Lira A, Haque E, Zhang Y, Callaghan S, Daigle M, Rousseaux MW, Slack RS, Albert PR, Vincent I, Woulfe JM, Park DS: Role of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson's disease. Neuron 2007, 55:37-52 (Pubitemid 46990825)
40. Anne SL, Saudou F, Humbert S: Phosphorylation of huntingtin by cyclin-dependent kinase 5 is induced by DNA damage and regulates wild-type and mutant huntingtin toxicity in neurons. J Neurosci 2007, 27:7318-7328 (Pubitemid 47037570)
41. Ahlijanian MK, Barrezueta NX, Williams RD, Jakowski A, Kowsz KP, McCarthy S, Coskran T, Carlo A, Seymour PA, Burkhardt JE, Nelson RB, McNeish JD: Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci USA 2000, 97:2910-2915 (Pubitemid 30159271)
42. Masliah E, Roberts ES, Langford D, Everall I, Crews L, Adame A, Rockenstein E, Fox HS: Patterns of gene dysregulation in the frontal cortex of patients with HIV encephalitis [Erratum appeared in J Neuroimmunol 2005, 162:197]. J Neuroimmunol 2004, 157:163-175
43. Achim CL, Heyes MP, Wiley CA: Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains. J Clin Invest 1993, 91:2769-2775 (Pubitemid 23182534)
44. Masliah E, Achim C, Ge N, DeTeresa R, Terry R, Wiley C: Spectrum of human immunodeficiency virus-associated neocortical damage. Ann Neurol 1992, 32:321-329
45. Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L: Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 1994, 367:188-193 (Pubitemid 24031702)
46. D'Hooge R, Franck F, Mucke L, De Deyn PP: Age-related behavioural deficits in transgenic mice expressing the HIV-1 coat protein gp120. Eur J Neurosci 1999, 11:4398-4402 (Pubitemid 30009272)
47. Ohshima T, Ward JM, Huh CG, Longenecker G, Veeranna, Pant HC, Brady RO, Martin LJ, Kulkarni AB: Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci USA 1996, 93:11173-11178 (Pubitemid 26333137)
48. Rockenstein E, Adame A, Mante M, Moessler H, Windisch M, Masliah E: The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. J Neural Transm 2003, 110:1313-1327 (Pubitemid 37500752)
49. Pham E, Crews L, Ubhi K, Hansen L, Adame A, Cartier A, Salmon D, Galasko D, Michael S, Savas JN, Yates JR, Glabe C, Masliah E: Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. FEBS J 2010, 277:3051-3067
50. Cole G, Dobkins K, Hansen L, Terry R, Saitoh T: Decreased levels of protein kinase C in Alzheimer brain [Erratum appeared in Brain Res 1991, 558:177]. Brain Res 1988, 452:165-170
51. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara, Sisk A, Mucke L: Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000, 287:1265-1269 (Pubitemid 30112148)
52. Rockenstein E, Mante M, Alford M, Adame A, Crews L, Hashimoto M, Esposito L, Mucke L, Masliah E: High beta-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels: implications for the treatment of Alzheimer disease. J Biol Chem 2005, 280:32957-32967 (Pubitemid 41368345)
53. Rockenstein E, Adame A, Mante M, Larrea G, Crews L, Windisch M, Moessler H, Masliah E: Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin. J Neural Transm 2005, 112:269-282 (Pubitemid 40179119)
54. Mucke L, Abraham C, Ruppe M, Rockenstein E, Toggas S, Alford M, Masliah E: Protection against HIV-1 gp120-induced brain damage by neuronal overexpression of human amyloid precursor protein (hAPP). J Exp Med 1995, 181:1551-1556
55. Biebl M, Cooper CM, Winkler J, Kuhn HG: Analysis of neurogenesis and programmed cell death reveals a self-renewing capacity in the adult rat brain. Neurosci Lett 2000, 291:17-20 (Pubitemid 30658102)
56. Cooper-Kuhn CM, Kuhn HG: Is it all DNA repair? Methodological considerations for detecting neurogenesis in the adult brain. Brain Res Dev Brain Res 2002, 134:13-21 (Pubitemid 34310233)
57. Biebl M, Winner B, Winkler J: Caspase inhibition decreases cell death in regions of adult neurogenesis. Neuroreport 2005, 16:1147-1150 (Pubitemid 41058458)
58. Schifitto G, Zhong J, Gill D, Peterson DR, Gaugh MD, Zhu T, Tivarus M, Cruttenden K, Maggirwar SB, Gendelman HE, Dewhurst S, Gelbard HA: Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol 2009, 15:176-186
59. Wen Y, Planel E, Herman M, Figueroa HY, Wang L, Liu L, Lau LF, Yu WH, Duff KE: Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J Neurosci 2008, 28:2624-2632 (Pubitemid 351348188)
60. Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, Rose JB, Crews L, Masliah E: Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 2007, 27:1981-1991
61. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B, Burns M, Krishnamurthy P, Wen Y, Bhat R, Lewis J, Dickson D, Duff K: Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 2005, 102:6990-6995 (Pubitemid 40675429)
62. Flaherty DB, Soria JP, Tomasiewicz HG, Wood JG: Phosphorylation of human tau protein by microtubule-associated kinases: gSK3beta and cdk5 are key participants. J Neurosci Res 2000, 62:463-472
63. Mookherjee P, Johnson GV: tau phosphorylation during apoptosis of human SH-SY5Y neuroblastoma cells. Brain Res 2001, 921:31-43 (Pubitemid 33096282)
64. Mattson MP: Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 2000, 1:120-129
65. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT: Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 2002, 103:26-35 (Pubitemid 36075309)
66. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L: Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754 (Pubitemid 46717684)
67. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wölfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Götz J: Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010, 142:387-397
68. Augustinack JC, Sanders JL, Tsai LH, Hyman BT: Colocalization and fluorescence resonance energy transfer between cdk5 and AT8 suggests a close association in pre-neurofibrillary tangles and neurofibrillary tangles. J Neuropathol Exp Neurol 2002, 61:557-564 (Pubitemid 34603004)
69. Gong CX, Liu F, Grundke-Iqbal I, Iqbal K: Post-translational modifications of tau protein in Alzheimer's disease. J Neural Transm 2005, 112:813-838 (Pubitemid 40655573)
70. Plattner F, Angelo M, Giese KP: The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem 2006, 281:25457-25465 (Pubitemid 44401934)
71. Vincent I, Rosado M, Davies P: Mitotic mechanisms in Alzheimer's disease. J Cell Biol 1996, 132:413-425
72. Schmidt ML, Lee VM, Trojanowski JQ: Relative abundance of tau and neurofilament epitopes in hippocampal neurofibrillary tangles. Am J Pathol 1990, 136:1069-1075 (Pubitemid 20188493)
73. Mandelkow EM, Mandelkow E: Tau in Alzheimer's disease. Trends Cell Biol 1998, 8:425-427
74. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski Hm: Microtubule-associated protein tau: a component of Alzheimer paired helical filaments. J Biol Chem 1986, 261:6084-6089 (Pubitemid 17207447)
75. Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon S, Li B, Liu F, Rahman A, Tanimukai H, Grundke-Iqbal I: tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 2005, 1739:198-210 (Pubitemid 40018538)
76. Dickson DW, Crystal HA, Mattiace LA, Masur DM, Blau AD, Davies P, Yen SH, Aronson MK: Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging 1992, 13:179-189
77. Achim CL, Adame A, Dumaop W, Everall IP, Masliah E; Neurobehavioral Research Center: Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. J Neuroimmune Pharmacol 2009, 4:190-199
78. Rempel HC, Pulliam L: HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS 2005, 19:127-135 (Pubitemid 40409531)
79. Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, Achim CL: Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS 2005, 19:407-411 (Pubitemid 40446187)
80. Nebuloni M, Pellegrinelli A, Ferri A, Bonetto S, Boldorini R, Vago L, Grassi MP, Costanzi G: Beta amyloid precursor protein and patterns of HIV p24 immunohistochemistry in different brain areas of AIDS patients. AIDS 2001, 15:571-575 (Pubitemid 32281351)
81. Ohshima T, Gilmore EC, Longenecker G, Jacobowitz DM, Brady RO, Herrup K, Kulkarni AB: Migration defects of cdk5(-/-) neurons in the developing cerebellum is cell autonomous. J Neurosci 1999, 19:6017-6026 (Pubitemid 29327935)
82. Engmann O, Giese KP: Crosstalk between Cdk5 and GSK3beta: implications for Alzheimer's disease. Front Mol Neurosci 2009, 2:2
83. Patrick GN, Zhou P, Kwon YT, Howley PM, Tsai LH: p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway. J Biol Chem 1998, 273:24057-24064 (Pubitemid 28435748)
84. Tanaka T, Veeranna, Ohshima T, Rajan P, Amin ND, Cho A, Sreenath T, Pant HC, Brady RO, Kulkarni AB: Neuronal cyclin-dependent kinase 5 activity is critical for survival. J Neurosci 2001, 21:550-558 (Pubitemid 32107444)
85. Lipton S: Requirement for macrophages in neuronal injury induced by HIV envelope protein gp120. Neuroreport 1992, 3:913-915
86. Pulliam L, Herndier BG, Tang NM, McGrath MS: Human immunodeficiency virus-infected macrophages produce soluble factors that cause histological and neurochemical alterations in cultured human brains. J Clin Invest 1991, 87:503-512
87. Lipton SA: AIDS-related dementia and calcium homeostasis. Ann N Y Acad Sci 1994, 747:205-224
88. Dreyer EB, Kaiser PK, Offermann JT, Lipton SA: HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. Science 1990, 248:364-367
89. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, Moulinoux JP: Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997, 243:527-536 (Pubitemid 27060443)
90. Bach S, Knockaert M, Reinhardt J, Lozach O, Schmitt S, Baratte B, Koken M, Coburn SP, Tang L, Jiang T, Liang DC, Galons H, Dierick JF, Pinna LA, Meggio F, Totzke F, Schächtele C, Lerman AS, Carnero A, Wan Y, Gray N, Meijer L: Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 2005, 280:31208-31219
91. Mazanetz MP, Fischer PM: Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov 2007, 6:464-479 (Pubitemid 47064569)
92. Menn B, Bach S, Blevins TL, Campbell M, Meijer L, Timsit S: Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models. PLoS ONE 2010, 5:e12117
93. Wood H: Stroke: S-roscovitine-a potential neuroprotectant for stroke. Nat Rev Neurol 2010, 6:527
94. Sallam H, Jimenez P, Song H, Vita M, Cedazo-Minguez A, Hassan M: Age-dependent pharmacokinetics and effect of roscovitine on Cdk5 and Erk1/2 in the rat brain. Pharmacol Res 2008, 58:32-37
95. Vita M, Abdel-Rehim M, Olofsson S, Hassan Z, Meurling L, Sidén A, Sidén M, Pettersson T, Hassan M: Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat. Eur J Pharm Sci 2005, 25:91-103 (Pubitemid 40602199)
96. Zhang M, Li J, Chakrabarty P, Bu B, Vincent I: Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick type C mice. Am J Pathol 2004, 165:843-853 (Pubitemid 39129292)
97. Hilton GD, Stoica BA, Byrnes KR, Faden AI: Roscovitine reduces neuronal loss, glial activation, and neurologic deficits after brain trauma. J Cereb Blood Flow Metab 2008, 28:1845-1859